Evaxion Biotech A/S is a Denmark-based clinical-stage biotechnology company, which specializes in the development of AI-driven immunotherapies to improve the lives of patients with cancer and infectious diseases. The Company decodes the human immune system to discover and develop immunotherapies to treat cancer and infectious diseases. Based on AI-immunology core technology, Evaxion is developing a pipeline of product candidates. In addition, Evaxion develops portfolio of vaccines to prevent bacterial and viral infections.

Employees

Sector

Biotechnology & Medical Research

Calendar

04-07 - Q4 2025 Earnings Release (Projected)

More about the company

Quotes

Date	Price	Change	Volume
13/02/26	3.380 $	+5.96%	4,545
12/02/26	3.190 $	-3.63%	31,413
11/02/26	3.310 $	-2.65%	19,000
10/02/26	3.400 $	-2.02%	27,854
09/02/26	3.470 $	+3.27%	53,172

Delayed Quote Nasdaq

More quotes

Income Statement and Estimates

More financial data

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

3.190USD

Average target price

12.33USD

Spread / Average Target

+286.62%

Consensus

EPS Estimates

Revisions to estimates

Quarterly revenue - Rate of surprise

Company calendar

Delayed Nasdaq Other stock markets 19:02:20 13/02/2026 +04			5-day change	1st Jan Change
3.380 ^USD	+5.96%		+0.60%	-29.14%

02-12	European Equities Traded in the US as American Depositary Receipts Decline in Thursday Trading	MT
02-06	European Equities Traded in the US as American Depositary Receipts Rise Sharply in Friday Trading; Little Changed for the Week	MT

Capitalization	26.61M 22.42M 20.46M 19.53M 36.27M 2.41B 37.51M 238M 94.52M 1.16B 99.78M 97.73M 4.06B	P/E ratio 2025 *	-160x	P/E ratio 2026 *	-213x
Enterprise value	26.61M 22.42M 20.46M 19.53M 36.27M 2.41B 37.51M 238M 94.52M 1.16B 99.78M 97.73M 4.06B	EV / Sales 2025 *	3.55x	EV / Sales 2026 *	4.35x
Free-Float	74.75%	Yield 2025 *	-	Yield 2026 *	-

02-12	European Equities Traded in the US as American Depositary Receipts Decline in Thursday Trading	MT
02-06	European Equities Traded in the US as American Depositary Receipts Rise Sharply in Friday Trading; Little Changed for the Week	MT
02-04	European Equities Traded in the US as American Depositary Receipts Rise in Wednesday Trading	MT
02-03	European Equities Traded in the US as American Depositary Receipts Edge Lower in Tuesday Trading	MT
01-30	European Equities Traded in the US as American Depositary Receipts Edge Lower in Friday Trading; Up for Week	MT
01-28	European Equities Traded in the US as American Depositary Receipts Fall Sharply in Wednesday Trading	MT
01-21	European Equities Traded in the US as American Depositary Receipts Rise in Wednesday Trading	MT
01-20	European Equities Traded in the US as American Depositary Receipts Fall in Tuesday Trading	MT
01-13	Evaxion A/S Expands AI-Immunology Platform Into Autoimmune Diseases	CI
01-08	European Equities Traded in the US as American Depositary Receipts Decline in Thursday Trading	MT
12-26	European Equities Traded in the US as American Depositary Receipts Little Changed in Friday Trading; Gains 2% for Week	MT
12-24	European Equities Traded in the US as American Depositary Receipts Rise in Wednesday Trading	MT
12-23	European Equities Traded in the US as American Depositary Receipts Rise in Tuesday Trading	MT

25/09/25	HC Wainwright Adjusts Evaxion Biotech Price Target to $16 From $14, Maintains Buy Rating	MT
03/03/25	Certain Ordinary Shares of Evaxion A/S are subject to a Lock-Up Agreement Ending on 3-MAR-2025.	CI
02/04/24	Ladenburg Thalmann Upgrades Evaxion Biotech to Buy From Neutral, Price Target is $8	MT
12/02/24	HC Wainwright Initiates Evaxion Biotech With Buy Rating, Price Target is $14	MT
21/12/23	Ladenburg Thalmann Downgrades Evaxion Biotech to Neutral From Buy	MT

Evaxion A/S Stock

Equities

EVAX

US29970R3030

Biotechnology & Medical Research

Valuation: Evaxion A/S

Chart: Evaxion A/S

Latest news: Evaxion A/S

Last Transcript: Evaxion A/S

Analysts' recommendations: Evaxion A/S

Press Releases: Evaxion A/S

News in other languages: Evaxion A/S

Quotes and Performance

Course Extremes

Managers and Directors: Evaxion A/S

Other Biotechnology & Medical Research

Financials

Company Profile

Quotes

Income Statement and Estimates

Analysts' Consensus

Quarterly revenue - Rate of surprise

01-14	Evaxion expands AI-Immunology platform into autoimmune diseases	AQ
01-13	Evaxion expands AI-Immunology™ platform into autoimmune diseases	AQ
01-07	Evaxion to present 2026 company milestones at Biotech Showcase conference in San Francisco next week	AQ
12-19	Evaxion provides update on MSD collaboration - retains global rights to Gonorrhea vaccine candidate EVX-B2	AQ
12-06	Evaxion presents new data for EVX-04, a cancer vaccine candidate for acute myeloid leukemia at ASH Annual Meeting	AQ

25/09/25	Wall Street : The waiting game
09/01/24	Evaxion annonce un plan visant à mettre en œuvre la modification du ratio de ses ADS
09/01/24	Evaxion kündigt Plan zur Änderung des ADS-Verhältnisses an
23/12/23	Clôture du financement par placement privé pour Evaxion Biotech
23/12/23	Evaxion Biotech gibt Abschluss einer Privatplatzierung bekannt

1 day	+3.61%
1 week	+0.60%
Current month	+6.29%
1 month	-33.73%
3 months	-40.81%
6 months	+11.18%
Current year	-29.14%

1 week	3.06	3.66
1 month	2.87	5.18
Current year	2.87	5.48
1 year	1.2	12.15
3 years	1.2	92.5
5 years	1.2	1,252
10 years	1.2	1,252

Manager	Title	Age	Since
Helena Tayton-Martin CEO	Chief Executive Officer	59	24/11/2025
Andreas Mattsson PRN	Corporate Officer/Principal	49	11/08/2008
Thomas Schmidt DFI	Director of Finance/CFO	53	01/11/2024

Director	Title	Age	Since
Marianne Søgaard CHM	Chairman	58	25/11/2020
Roberto Prego Pineda BRD	Director/Board Member	56	01/01/2018
Lars Holtug BRD	Director/Board Member	68	25/05/2021

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5d. change	1-year change	3-years change	Capi.($)
EVAXION A/S	+5.96%	+0.60%	+29.50%	-95.67%	26.61M
LONZA GROUP AG	+3.94%	+0.23%	-13.31%	-4.88%	45.48B
BEONE MEDICINES AG	+0.98%	-1.20%	+55.07%	+42.67%	38.33B
CELLTRION, INC.	-0.21%	+9.43%	+38.51%	+60.03%	36.26B
IQVIA HOLDINGS INC.	+0.85%	-9.31%	-13.27%	-26.74%	28.64B
REVOLUTION MEDICINES, INC.	+0.57%	+0.99%	+138.27%	+285.49%	18.82B
IONIS PHARMACEUTICALS, INC.	+0.09%	-5.18%	+170.25%	+106.76%	13.25B
ASCENDIS PHARMA A/S	+0.64%	-1.31%	+53.86%	+92.49%	13.39B
EUROFINS SCIENTIFIC SE	+2.00%	-3.97%	+29.31%	-3.26%	13.41B
REGENCELL BIOSCIENCE HOLDINGS LIMITED	+3.17%	+16.78%	+33,657.96%	+4,215.96%	14.35B
Average	+1.61%	+1.11%	+3,414.62%	+467.29%	22.19B
Weighted average by Cap.	+1.53%	-0.49%	+2,214.46%	+321.26%

	2025 *	2026 *
Net sales	7.5M 6.32M 5.77M 5.51M 10.22M 679M 10.57M 67M 26.64M 327M 28.13M 27.55M 1.14B	6.11M 5.15M 4.7M 4.49M 8.33M 554M 8.62M 54.59M 21.71M 267M 22.92M 22.45M 932M
Net income	-5.65M -4.76M -4.35M -4.15M -7.7M -512M -7.97M -50.47M -20.07M -247M -21.19M -20.75M -861M	-7.86M -6.62M -6.04M -5.77M -10.71M -712M -11.08M -70.19M -27.91M -343M -29.46M -28.86M -1.2B
Net Debt	-	-